+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 8 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are evaluating the effects of camoteskimab in adults aged 18 to 65 with moderate-to-severe atopic dermatitis. This phase 2b, multicenter, randomized, double-blind, placebo-controlled study aims to assess the efficacy and safety of camoteskimab compared to placebo. Participants include those who are treatment-naive or have had an inadequate response to previous biologic therapies. The study has two parts Part 1 is a 24-week placebo-controlled period where participants are randomly assigned to one of three camoteskimab dose levels or placebo, all administered by subcutaneous injection. In Part 2, an extension period, all participants receive camoteskimab. This design allows comparison of different dose levels and monitoring of long-term treatment effects. Participants will be assessed regularly throughout the study with measures including the Eczema Area and Severity Index EASI, Investigator Global Assessment IGA, and peak pruritus numerical rating scale PP-NRS. Safety and efficacy will be monitored through these assessments over 24 weeks and beyond. The study includes signing informed consent and adherence tracking, with the primary outcome focused on percentage change in EASI score from baseline to Week 24.

Age: 18Years - 65YearsAll GendersPhase 2
85 locations
C

Actively Recruiting

Researchers are evaluating how the study medicine CagriSema helps adults living with obesity, with or without type 2 diabetes, lose weight. This clinical trial compares two different doses of CagriSema with semaglutide, a medicine already prescribed for weight loss. The study aims to understand the safety and effectiveness of CagriSema in reducing body weight over time. Participants are randomly assigned to receive one of three treatments CagriSema at dose level 1, CagriSema at dose level 2, or semaglutide. Each treatment is given once weekly as a subcutaneous injection over a 72-week period. The study lasts about 83 weeks in total to include all treatment and follow-up time. During the study, participants will have regular visits for assessments including body weight, body mass index, waist circumference, cholesterol levels, and blood sugar control. Questionnaires on physical function and quality of life will also be completed. Researchers will track any side effects and serious adverse events throughout the study and after treatment ends, monitoring safety for up to 80 weeks.

Age: 18Years +All GendersPhase 3
303 locations
L

Actively Recruiting

Researchers are studying the long-term safety and tolerability of KarXT for treating mania or mania with mixed features in adults with Bipolar-I disorder. This phase 3 open-label extension trial focuses on participants who have either completed prior related studies or are newly diagnosed with specific criteria. The study aims to monitor adverse events and changes in symptoms over an extended period. Participants receive KarXT at specified doses, with some possibly receiving additional therapeutic doses of Lithium, Valproate, or Lamotrigine. The study does not involve placebo and is designed as a single-group intervention. The treatment and monitoring continue for up to 54 weeks, focusing on safety and symptom assessments. During the study, participants undergo regular evaluations including psychiatric assessments and safety monitoring. Researchers track treatment-emergent adverse events, serious adverse events, and changes in suicidal ideation using the Columbia-Suicide Severity Rating Scale. Additional assessments include rating scales for movement disorders and urinary symptoms. The total participation period extends up to about one year, with ongoing safety and tolerability evaluations.

Age: 18Years - 65YearsAll GendersPhase 3
184 locations
E

Actively Recruiting

Researchers are evaluating DT-101 as a potential treatment for adults with Major Depressive Disorder MDD. This study compares the effects of DT-101 to a placebo to understand how it may impact depression symptoms. The study also aims to assess the safety and tolerability of DT-101 in this population. Participants will be randomly assigned to receive one of two versions of DT-101 or a placebo. The study involves physical and neurological exams, blood and urine sample collection, and clinical assessments. Blood samples will also be analyzed to study how DT-101 is absorbed and processed by the body and to explore genetic factors that may influence response to the drug. Throughout the study, participants will attend clinic visits approximately every two weeks for health checks and to complete questionnaires about their depression. Researchers will monitor changes in depression severity using the Montgomery sberg Depression Rating Scale MADRS and other clinical measures over 42 days. Safety and ongoing suitability for participation will be regularly evaluated, with the total study duration extending up to about six weeks.

Age: 18Years - 75YearsAll GendersPhase 2
43 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of adding KarXT to existing treatments for mania in adults with Bipolar-I Disorder. This trial focuses on participants experiencing an acute manic episode, with or without mixed features, who are already taking lithium, valproate, or lamotrigine. The study aims to improve mania symptoms, measured by changes in the Young Mania Rating Scale after five weeks. Participants will be randomly assigned to receive either KarXT in addition to their mood stabilizer or a placebo plus their mood stabilizer. The treatments are given in specified doses over the study period, with careful monitoring of side effects and other health measures. The study includes a double-blind design, meaning neither participants nor researchers know which treatment is given to ensure unbiased results. During the trial, participants will undergo regular assessments including psychiatric evaluations, rating scales for mania and other symptoms, and safety monitoring up to seven weeks. Researchers will track symptom changes, treatment responses, and any adverse events. Participants are involved in scheduled visits for evaluations and to maintain stable mood stabilizer doses. The total participation lasts until the primary outcome is measured at week five, with additional safety follow-up up to week seven.

Age: 18Years - 65YearsAll GendersPhase 3
109 locations
E

Actively Recruiting

Researchers are evaluating the efficacy and safety of KarXT for treating manic episodes in adults with Bipolar-I Disorder. This Phase 3, randomized, double-blind, placebo-controlled study focuses on adults experiencing an acute episode of mania or mania with mixed features. The study aims to compare KarXT to placebo during a 3-week inpatient treatment period to assess symptom improvement. Participants will be randomly assigned to receive either KarXT or a placebo with flexible dosing during the 3-week inpatient phase. Prior to treatment, participants must undergo a screening period and psychotropic medications must be washed out within 14 days before starting. After the treatment phase, there is a safety follow-up period, with the entire study lasting no more than seven weeks. During the study, participants will be hospitalized for close monitoring. Researchers will assess symptoms using the Young Mania Rating Scale and Clinical Global Impressions-Bipolar at baseline and week 3. Safety evaluations will continue through follow-up visits. The main outcome is the change in mania symptoms after 3 weeks of treatment, with additional measures of clinical response and safety observed throughout the study.

Age: 18Years - 65YearsAll GendersPhase 3
74 locations
P

Actively Recruiting

Researchers are evaluating the drug NBI-1117570 for its effects on behavioral and psychological symptoms in adults with schizophrenia who need inpatient hospitalization. This phase 2a study compares NBI-1117570 to a placebo to assess its efficacy, safety, tolerability, and how the drug is processed in the body. Participants will be randomly assigned to one of three groups a lower-dose NBI-1117570 group, a higher-dose NBI-1117570 group, or a placebo group. The drug and placebo are given orally. The study uses a parallel design with quadruple masking to maintain blinding. The primary treatment period lasts 35 days, after which safety and adverse events are monitored up to 49 days. During the study, participants will have assessments to measure changes in schizophrenia symptoms using the Positive and Negative Syndrome Scale PANSS. Researchers will also track any treatment-emergent adverse events throughout the treatment and follow-up periods. The trial is sponsored by Neurocrine Biosciences and runs from February 2026 to August 2027.

Age: 18Years - 55YearsAll GendersPhase 2
6 locations
P

Actively Recruiting

Researchers are evaluating the safety, tolerability, and treatment response of GXV813 in adults hospitalized with schizophrenia who are experiencing an acute episode. This Phase 2a study aims to better understand how GXV813 affects symptoms of schizophrenia compared to a placebo in a controlled hospital setting. Participants will be randomly assigned to receive either GXV813 or a placebo, both given orally. The study uses a parallel-group design with quadruple masking to minimize bias. Treatment and observations will last for up to 6 weeks during hospitalization, focusing on symptom changes and drug pharmacokinetics. During the study, participants will be closely monitored with psychiatric assessments including the Positive and Negative Symptom Scale PANSS and Clinical Global Impression-Severity CGI-S scale. Researchers will also track safety, tolerability, and drug levels in the blood. The total participation time is about 6 weeks, with regular evaluations to measure changes from baseline symptoms and any adverse events.

Age: 18Years - 65YearsAll GendersPhase 2
16 locations